#32585
Re: Farmas USA
PSTI
el estrechamiento de las bollinger es lo más llamativo, pero no hay volumen.
Se está hablando de:
#32586
Re: Farmas USA
18k shares en pre al calor del anuncio de la conferencia
choca de nuevo en 5,59 .... :(
AMRN
"H.C. Wainwright upgraded Amarin with a $10 price target citing an attractive risk/reward at current levels."
http://finance.yahoo.com/news/amarin-upgraded-buy-neutral-h-111210651.html
Aqui no va ANCHOR incluido. Vamos, seguro.
edito: 75k shares en pre. inusual
#32587
Re: Farmas USA
http://www.dailyfinance.com/2013/08/12/deadline-alert-rigrodsky-long-pa-reminds-sharehold/
.... Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ GM: VNDA) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company ...
VNDA
#32588
Re: Farmas USA
MACK recibe orphan status para su MM-111
"FDA has granted two separate orphan drug designations for its bispecific antibody MM-111, for the treatment of esophageal cáncer"
Esto lo debían saber los HF el viernes, de ahí la subida que hubo. Ahora que se mantenga y rebote de una vez.
Subiendo un 6.93% en premkt
#32589
Re: Farmas USA
AMRN
H.C. Wainwright upgraded Amarin Corporation (NASDAQ: AMRN) from Neutral to Buy.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#32590
Re: Farmas USA
Hola Anaramos, ¿qué tal?
¿Podrías contarme para que sirven los diseños de ONVO?
Un saludo
#32591
Re: Farmas USA
CTIX en pre moviéndose....a lo mejor tenemos hoy la reacción a la new de ayer...cerró en 1,96, y en pre, 1,99x2,00, con 4178 títulos....
Un saludo
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company is on track to commence a clinical study for its anti-psoriasis drug Prurisol™. The Company has completed and submitted all regulatory documents necessary for the clinical study and anticipates receiving the regulatory documents this week allowing for the importation of Prurisol™ into Europe to begin the clinical study.
"We are pleased to inform shareholders that we have now completed the regulatory matters necessary for a clinical study of Prurisol and that we have been notified by our contract manufacturer, Dr. Reddy's Laboratories (RDY), that Prurisol is ready for shipping to the clinical site," Leo Ehrlich, CEO at Cellceutix, stated. "We are planning to have the drug shipped in August and the trial to commence shortly thereafter. The clinical site has been notified to begin patient recruitment. We are optimistic about the potential for Prurisol™ to reproduce the laboratory results which showed the drug to effectively eliminate all signs of psoriasis."
In other news, Cellceutix's clinical trial of its anti-cancer drug Kevetrin™ is progressing and is presently in the dose escalation phase as maximum tolerated dose (MTD) has not yet been reached. The testing for p21, a biomarker study at the Harvard Cancer Center lab, has not yet begun. Dr. Krishna Menon, Cellceutix's Chief Scientific Officer, commented, "We understand that there were internal priorities at the lab and because these are very sophisticated and complex tests, the process can be detailed and somewhat time consuming. We are hopeful that these important biomarker studies will soon be processed and when they are, we will share those results."
The Company is also pleased to report that it is currently planning to uplist (moving from an over-the-counter stock to a national securities exchange like NASDAQ-CM or NYSE-MKT). "Due to the Company's strong financial backing from our $10 million equity line from Aspire Capital, and further progress in our clinical trials, we are intending to move to a senior exchange," commented Leo Ehrlich, CEO. "Over the coming weeks we will be interviewing for the positions of independent directors to meet the requirements for an uplisting which we hope will increase liquidity and unlock inherent value in our stock. We will be presenting at the Rodman and Renshaw Annual Global Investment Conference in September where we will discuss in detail the Company's progress, growth objectives and plans for 2013-2014."
CTIX
#32592
Re: Farmas USA
Si la listaran en NASDAQ o NYSE, podríamos doblar, como mínimo, al igual que pasó con IMUC...
Un saludo
CTIX
Edito....van entrando más en pre y eso que en CTIX no hay pre....
Edito otra vez....ya van 42k en 2 minutos, subiendo un 2% en los 2$.....a ver qué va a pasar....
